104 related articles for article (PubMed ID: 14701983)
1. The clinical impact of camera-based positron emission tomography imaging in patients with recurrent colorectal cancer.
Miller E; Lerman H; Gutman M; Figer A; Livshitz G; Even-Sapir E
Invest Radiol; 2004 Jan; 39(1):8-12. PubMed ID: 14701983
[TBL] [Abstract][Full Text] [Related]
2. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
[TBL] [Abstract][Full Text] [Related]
3. Role of (18)F-FDG dual-head gamma-camera coincidence imaging in recurrent or metastatic colorectal carcinoma.
Even-Sapir E; Lerman H; Figer A; Rabau M; Livshitz G; Inbar M; Gutman M
J Nucl Med; 2002 May; 43(5):603-9. PubMed ID: 11994521
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
[TBL] [Abstract][Full Text] [Related]
5. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study.
Kalff V; Hicks RJ; Ware RE; Hogg A; Binns D; McKenzie AF
J Nucl Med; 2002 Apr; 43(4):492-9. PubMed ID: 11937593
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
7. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
[TBL] [Abstract][Full Text] [Related]
8. Detection of occult disease in breast cancer using fluorodeoxyglucose camera-based positron emission tomography.
Pecking AP; Mechelany-Corone C; Bertrand-Kermorgant F; Alberini JL; Floiras JL; Goupil A; Pichon MF
Clin Breast Cancer; 2001 Oct; 2(3):229-34. PubMed ID: 11899417
[TBL] [Abstract][Full Text] [Related]
9. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
Pelosi E; Deandreis D
Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
[TBL] [Abstract][Full Text] [Related]
10. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in colorectal cancer.
Flamen P
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer.
Simó M; Lomeña F; Setoain J; Pérez G; Castellucci P; Costansa JM; Setoain-Quinquer J; Doménech-Torné F; Carrió I
Nucl Med Commun; 2002 Oct; 23(10):975-82. PubMed ID: 12352596
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET.
Montravers F; Grahek D; Kerrou K; Younsi N; Petegnief Y; de Beco V; Colombet-Lamau C; Talbot JN
Nucl Med Commun; 2004 Feb; 25(2):105-13. PubMed ID: 15154697
[TBL] [Abstract][Full Text] [Related]
16. The role of [18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma.
Wudel LJ; Delbeke D; Morris D; Rice M; Washington MK; Shyr Y; Pinson CW; Chapman WC
Am Surg; 2003 Feb; 69(2):117-24; discussion 124-6. PubMed ID: 12641351
[TBL] [Abstract][Full Text] [Related]
17. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
[TBL] [Abstract][Full Text] [Related]
18. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
19. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
[TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography in the management of recurrent colorectal cancer: a review.
Watson AJ; Lolohea S; Robertson GM; Frizelle FA
Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
